Elanco Animal Health Incorporated $ELAN Shares Sold by Private Management Group Inc.

Private Management Group Inc. lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 17.1% in the second quarter, HoldingsChannel reports. The fund owned 678,317 shares of the company’s stock after selling 139,802 shares during the quarter. Private Management Group Inc.’s holdings in Elanco Animal Health were worth $16,693,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Elanco Animal Health in the 2nd quarter worth $38,000. Root Financial Partners LLC boosted its holdings in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in Elanco Animal Health during the fourth quarter valued at about $41,000. Finally, Bessemer Group Inc. increased its stake in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Paul Herendeen acquired 10,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This represents a 9.83% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael J. Harrington acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares in the company, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 63,198 shares of company stock valued at $1,473,109. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $24.16 on Friday. The stock’s 50 day moving average price is $24.62 and its 200 day moving average price is $24.01. The firm has a market capitalization of $12.07 billion, a PE ratio of -58.93, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. KeyCorp boosted their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Citigroup raised their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.